Valemetostat Tosilate

6 trials 3 recruiting Orphan designation

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

3 Recruiting

2 Completed trials

4 Sponsors

5 Countries

Phase II

Phase I/II

Phase I (Other)

Phase II: 3 Phase I/II: 2 Phase I (Other): 1

Oversight events:

3 temporary halts 1 urgent safety measure across 1 trial

View oversight register →

Indications tested

Diffuse large B-cell lymphoma 1 Non-small cell lung cancer metastatic 1 Marginal zone lymphoma 1 Mantle cell lymphoma 1 Lymphoma 1

Sponsors using this IMP

Daiichi Sankyo Inc. 3 Celgene Corp. 1 Institut Gustave Roussy 1 LYSARC 1

All trials

6 total

An open label phase II platform modular study exploring the efficacy and safety of the Valemetostat (EZH1/2 inhibitor) in patients with sele… Recruiting

2024-519788-16-00 Phase II 1 country Institut Gustave Roussy
A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma Recruiting

2024-516181-11-00 Phase II 2 countries LYSARC
An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) Recruiting

2024-515690-10-00 Phase I/II 4 countries Celgene Corp.
Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma Ended

2023-507381-13-00 Phase II 3 countries Daiichi Sankyo Inc.
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors Halted

2024-516916-93-00 Phase I (Other) 3 countries Daiichi Sankyo Inc.
A Study of Valemetostat Tosylate Plus Pembrolizumab versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations Ended

2024-519671-26-00 Phase I/II 3 countries Daiichi Sankyo Inc.

Showing 1–6 of 6 trials

← All drugs A–Z